Investors

Shield Therapeutics is well positioned to become a fast growing, independent, international specialty pharmaceutical company.

Why invest in Shield Therapeutics?

Shield has transformed from a development-focused, privately owned company into a PLC with increasingly commercially focused, customer-facing organisation set up to sell our innovative and value-added specialty pharmaceuticals that solve patients’ unmet medical needs.

£500m+

Annual Revenue

Targeted for Ferracru

£200m+

Annual Revenue

Targeted for PT20

£60m

Amount Raised

Since 2010

London, UK

One Euston Square
40 Melton Street
London, NW1 2FD

t+44 (0) 207 186 8500

einfo@shieldtx.com

Newcastle, UK

Northern Design Centre
Baltic Business Quarter
Gateshead Quays, NE8 3DF

t+44 (0) 191 511 8500

einfo@shieldtx.com

Wollerau, Switzerland

Shield Therapeutics
c/o Shield Holdings AG
Sihleggstrasse 23, 8832 Wollerau

t+41 (0) 435 080 781

einfo@shieldtx.com

Munich, Germany

Shield Therapeutics (DE)
Leopoldstr. 23
80802 München, Germany

einfo@shieldtx.com